Shionogi & Co Ltd represents values of innovation, integrity, and commitment to improving global health. The company's corporate philosophy is centered around the "Supplier of smiles" concept, aiming to contribute to the quality of life and healthcare of people worldwide. Shionogi is dedicated to delivering innovative pharmaceuticals and healthcare solutions, focusing on areas such as infectious diseases, cancer, pain management, and neuroscience. The company's emphasis on research and development, ethical practices, and strong partnerships enables Shionogi to fulfill its mission of creating a healthier future for society.

Shionogi & Co Ltd is primarily present in Japan, where the company is headquartered.

Shionogi & Co Ltd has achieved several significant milestones throughout its history. In recent years, the company successfully developed and gained approval for several groundbreaking medications, including the antiretroviral drug Delstrigo™ and the antibiotic Fetroja™. Shionogi has also established strategic partnerships with renowned pharmaceutical companies to enhance its research and development capabilities. Additionally, the company has been actively expanding its global reach, particularly in the United States and Europe, through various initiatives and collaborations. With an impressive track record of innovation and a commitment to improving global health, Shionogi & Co Ltd continues to make significant strides in the pharmaceutical industry.

Shionogi & Co Ltd is a renowned pharmaceutical company based in Japan. With a rich history dating back to 1878, Shionogi has established itself as a leading player in the global healthcare industry. The company is known for its focus on research and development, aiming to discover innovative solutions to various medical challenges. Shionogi's commitment to addressing unmet medical needs has led to the development of groundbreaking drugs and treatments. Over the years, Shionogi has expanded its operations worldwide, forming strategic partnerships and collaborations to deliver high-quality pharmaceutical products to patients around the globe. Through a steadfast dedication to improving human health, Shionogi has become a respected name in the pharmaceutical field.

The main competitors of Shionogi & Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc., and Daiichi Sankyo Co Ltd.

Shionogi & Co Ltd is primarily active in the pharmaceutical industry.

Shionogi & Co Ltd is a pharmaceutical company that focuses on developing and marketing innovative drugs. Their business model revolves around research and development, manufacturing, and sales of pharmaceutical products. Shionogi aims to provide solutions to unmet medical needs by focusing on therapeutic areas such as infectious diseases, pain, cardiovascular disorders, and oncology. By investing in cutting-edge research, Shionogi strives to create new treatments and improve existing therapies. With a strong commitment to quality and patient-centric approach, Shionogi seeks to contribute to the well-being of society by delivering safe, effective, and high-quality pharmaceutical products.

Shionogi & Co에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Shionogi & Co에 대한 현재 KUV는 계산할 수 없습니다.

Shionogi & Co에 대한 AlleAktien 품질 점수는 7/10입니다.

Shionogi & Co 매출은 438.27 조. JPY입니다.

Shionogi & Co 이익은 170.44 조. JPY입니다.

Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. The company was founded in 1878 and specializes in the development and marketing of innovative drugs. Shionogi combines its own research capabilities with strategic partnerships with other companies. The business model of Shionogi is based on three core divisions: 1. Pharma: This division includes the clinical development and marketing of prescription drugs. Shionogi has a wide range of medications in various therapeutic areas such as oncology, infectious diseases, diabetes, cardiovascular diseases, and neurological diseases. One of Shionogi's most well-known medications is the antibiotic Fetroja for the treatment of respiratory and urinary tract infections. 2. Consumer Healthcare: This division includes the development and marketing of over-the-counter products such as dietary supplements or cosmetics. Some of Shionogi's well-known products include Dequadin lip balm, which helps with chapped lips and cold sores, and Allelock antiallergic medication used for allergic rhinitis. 3. Research & Development: This division focuses on the research and development of innovative drugs and therapy options. Shionogi invests a considerable portion of its revenue in research and development each year. The company also collaborates closely with academic institutions and other pharmaceutical companies to accelerate the research and development of new drugs. Additionally, Shionogi has a strong focus on the Asian market. The company has subsidiaries in several Asian countries and has made significant investments in research facilities in China and Singapore in recent years. In 2020, Shionogi had a revenue of approximately 1.1 trillion yen (around 8.6 billion euros) and employed around 6,000 people in Japan and worldwide. In summary, Shionogi's business model is based on the development and marketing of innovative drugs and therapy options. The company combines its own research capabilities with strategic partnerships and operates in three core divisions: Pharma, Consumer Healthcare, and Research & Development. Shionogi also has a strong presence in the Asian market and has invested in research facilities in China and Singapore in recent years.

Shionogi & Co은(는) 연간 번의 배당을 통해 120 JPY의 배당금을 지급합니다.

Shionogi & Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Shionogi & Co의 ISIN은 JP3347200002입니다.

Shionogi & Co의 WKN은 855648입니다.

Shionogi & Co의 티커는 4507.T입니다.

지난 12개월 동안 Shionogi & Co은(는) 66 JPY 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Shionogi & Co은(는) 69.16 JPY의 배당금을 지급할 것으로 예상됩니다.

Shionogi & Co의 현재 배당 수익률은 입니다.

Shionogi & Co은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Shionogi & Co은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 69.16 JPY의 배당금이 예상됩니다. 이는 배당수익률 2.63 %에 해당합니다.

Shionogi & Co은 '건강' 섹터에 속합니다.

Shionogi & Co의 마지막 배당금을 33 JPY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Shionogi & Co는 113.333 JPY를 배당금으로 지급했습니다.

Shionogi & Co의 배당금은 JPY에 지급됩니다.